TGTX Stock — TG Therapeutics Inc.: Cash, EV, Pipeline

Share price

$56.87

Market cap

$8,705.0M

Cash

$552.2M

Enterprise value

$8,898.2M

Balance sheet

Cash	$552.2M
Debt	$745.4M
Net cash	-$193.2M
Enterprise value	$8,898.2M
Basic shares	153.1M shares
Fully diluted shares	169.2M shares
Fully diluted market cap	$9,619.8M
Cash per share	$3.61

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TGTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 12, 2026 - Jan 23, 2027	Ublituximab	Phase 3	Relapsing Multiple Sclerosis	—
Jan 12 - Feb 23	Azercabtagene zapreleucel (azer-cel)	Phase 1	B-cell Mediated Autoimmune Disorders	—
Mar 4 - Apr 15	Ublituximab	Phase 3	Relapsing Multiple Sclerosis	—
Sep 11 - Oct 23	Ublituximab	Phase 2	Multiple Sclerosis	—
Aug 12 - Sep 23	Ublituximab	Phase 2	Myasthenia Gravis	—
Jan 23 - Mar 6	Ublituximab	Phase 2	Schizophrenia	—
Feb 12 - Mar 26	Ublituximab	Phase 2/3	Relapsing Multiple Sclerosis	—
Jul 12 - Aug 23	Ublituximab	Phase 3	Relapsing Multiple Sclerosis (RMS)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BRIUMVI

Approved · Active Modality: anti-CD20 monoclonal antibody

Aliases ublituximab-xiiy, ublituximab

Target CD20

Partnerships LFB Group (exclusive worldwide license, ex-France/Belgium); Neuraxpharm (ex-US commercialization)

Indications

relapsing forms of multiple sclerosis (RMS) (Approved)
relapsing forms of multiple sclerosis (subcutaneous formulation) (Phase 3)

Status note IV formulation approved; subcutaneous formulation in Phase 3 pivotal program (enrollment commenced September 2025); one row per candidate, not per formulation.

Azer-cel

Phase 1 · Active Modality: allogeneic CD19-directed CAR T cell therapy

Target CD19

Partnerships Precision BioSciences (global exclusive license for autoimmune/non-oncology); MaxCyte (platform)

Indications

autoimmune diseases (Phase 1)
progressive multiple sclerosis (Phase 1)

Status note IND cleared August 2024; first progressive MS patient dosed August 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ublituximab
Lead indication	Relapsing Multiple Sclerosis
Lead phase	Phase 3
Active trials	12

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07211633	Phase 3	Active, not recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis	—
NCT05877963	Phase 3	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis	—
NCT04130997	Phase 3	Active, not recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis (RMS)	—
NCT07220252	Phase 2/3	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis	—
NCT07503873	Phase 2	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Multiple Sclerosis	—
NCT07673744	Phase 2	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Myasthenia Gravis	—
NCT07680946	Phase 2	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Schizophrenia	—
NCT06680037	Phase 1	Recruiting	Sponsor	TG Therapeutics, Inc.	—	B-cell Mediated Autoimmune Disorders	—
NCT06143514	Not disclosed	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis	—
NCT06433752	Not disclosed	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Relapsing Multiple Sclerosis; Multiple Sclerosis	—
NCT06433765	Not disclosed	Recruiting	Sponsor	TG Therapeutics, Inc.	—	Multiple Sclerosis	—
NCT07577583	Not disclosed	Not yet recruiting	Sponsor	TG Therapeutics, Inc.	—	B-cell Mediated Autoimmune Disorders	—

Sponsor-matched active trials from ClinicalTrials.gov (12 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 12 active trials for TG Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	0	-358,800	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TGTX — TG Therapeutics Inc.